2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

Johnson & Johnson and Amgen have outperformed the broader market in 2026 despite facing near-term challenges. JNJ's medtech division struggles with its Impella heart pump facing safety concerns and recalls, but its innovative medicines segment and new products like OTTAVA robotic surgery system offer long-term growth. Amgen faces regulatory pressure on Tavneos and patent losses on denosumab, but strong pipeline candidates like MariTide and established growth drivers like Tezspire and Tepezza support its outlook. Both companies maintain excellent dividend track records, making them solid long-term income investments.